CN-202

N/A

Report date: 2023/12/31 20:00:33

Base Information

Drug NameCN-202

Drug Alias NameCN-202

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Programmed death-ligand 1Anti-TGF-β

TargetsProgrammed death-ligand 1Transforming growth factor beta

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesCuron Biopharmaceutical Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCuron Biopharmaceutical Ltd

Inactive CompaniesCuron Biopharmaceutical (Australia) Co Pty Ltd

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A